Close Menu

NEW YORK (360Dx) – HemoCue announced today its HemoCue Hb 801 System has received 510(k) clearance from the US Food and Drug Administration for marketing.

The platform enables healthcare providers to assess the hemoglobin levels of patients at the point of care in a clinic and quantitatively measures hemoglobin in capillary or venous whole blood. It is intended for use on adults, adolescents, children, and infants older than one month of age.

The HemoCue Hb 801 System comprises an analyzer and microcuvettes and is CLIA-waived, said HemoCue, which is based in Sweden.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.